
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly is expanding manufacturing, innovating Zepbound pricing, and competing in the GLP-1 market. Jaypirca's EU approval and ad campaigns against unapproved drugs highlight strategic moves.
Eli Lilly expands US manufacturing with a $27B investment amid rising demand for Zepbound & Mounjaro. Plus, Jaypirca receives positive EU recommendation.
Eli Lilly's $27B US investment signals a strategic shift amid rising demand for Zepbound and Mounjaro, addressing tariffs and bolstering supply chain resilience.
Eli Lilly strategically adjusts Zepbound pricing, navigates competition with Novo Nordisk, and expands access via LillyDirect. The company's R&D pipeline extends beyond weight loss.
Eli Lilly strategically navigates the GLP-1 market with Zepbound price adjustments and LillyDirect, facing competition from Novo Nordisk and policy risks.
Eli Lilly navigates 2025 with GLP-1 therapies, strategic R&D investments, and expansion into new therapeutic areas, demonstrating innovation and long-term value creation.
Eli Lilly strategically shifts to Alzheimer's and ALS, leveraging GLP-1 success. A $550M weight-loss pill investment and projected 32% revenue growth highlight potential.
Eli Lilly leverages its weight loss drug success to invest in groundbreaking Alzheimer's and ALS research, driving a strategic pivot.
This comprehensive analysis examines Eli Lilly's GLP-1 drugs market impact, strategic developments, and future growth opportunities.
Latest analysis reveals Eli Lilly’s strategic GLP-1 focus and diversified R&D, driving robust revenue growth and future potential.